Posters

Visual rehabilitation in macular degeneration using the new IOLAMD Eyemax technology for phakic and pseudophakic eyes

Poster Details

First Author: F. Hengerer GERMANY

Co Author(s):    T. Kohnen   I. Conrad-Hengerer                 

Abstract Details

Purpose:

To determine the safety and efficacy of the iolAMD Eyemax™ technology (London Eye Hospital Pharma, London, UK) in a pilot study of pseudophakic patients or with cataract and dry age-related macular degeneration.

Setting:

Department of Ophthalmology, Goethe-University Frankfurt am Main, Frankfurt, Germany

Methods:

A retrospective, nonrandomized clinical trial was conducted consisting of 6 eyes (6 patients) with cataract and 6 pseudophakic eyes (6 patients) with advanced stages of dry or stable wet AMD. The cataract surgery followed by IOL implantation was performed using standard phacoemulsification techniques. In pseudophakic eyes the iolAMD Eyemax add on lens was implanted. Outcomes were intra- and postoperative complications, subjective and objective visual acuity improvement, visual field changes and postoperative diplopia.

Results:

Twelve eyes of 12 patients were evaluated. The surgeries were uneventful. All eyes gained improvement in monocular near and distance vision at 1-months postoperative visit. No patient recognized diplopia for distance vision.

Conclusions:

These early results showed that iolAMD Eyemax is a promising technology improving visual acuity in eyes with macular degeneration. Secondary lens implantation in pseudophakic eyes did not increase intraocular pressure. All surgeries were safely performed

Financial Disclosure:

NONE